PHAT vs CTMX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHAT · Phathom Pharmaceuticals$5.25 ▲ 3.35%
CTMX · CytomX$2.19 ▲ 2.34%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHAT -61.8%
- CTMX -47.7%
Head to head
| Metric | PHAT | CTMX |
|---|---|---|
| Price | $5.25 | $2.19 |
| Change today | ▲ 3.35% | ▲ 2.34% |
| Market cap | $426.78M | $477.43M |
| Return, 3 months | -38.7% | -36.3% |
| Return, year to date | -68.4% | -48.6% |
| Return, 1 year | -60.4% | -39.5% |
| P/E (TTM) | – | – |
| P/B | -1.2 | 1.7 |
| P/E percentile vs own 5y | 5th | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +71.1% | -92.4% |
| Net profit growth (YoY) | +53.6% | -13,319.5% |
| Gross margin | 80.7% | – |
| Operating margin | -9.3% | -476.2% |
| Net margin | -30.2% | -435.2% |
| Return on equity | – | -37.8% |
| Analyst target vs. price | +231.4% | +493.6% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 32 | 41 |
| 30-day volatility | 83.8% | 67.9% |
| Max drawdown, 1 year | -71.9% | -68.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTMX is the largest of the group by market value.
- CTMX has returned the most over the past year.
- PHAT is growing revenue fastest.
- PHAT keeps the most profit per dollar of sales.
- CTMX has been the calmest stock over the last 30 days.